8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate sulfate (1:1) | 5908-99-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate sulfate (1:1)
• 英文别名: (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) (2R)-3-hydroxy-2-phenylpropanoate,sulfuric acid；L-HYOSCYAMINE HEMISULFATE SALT；Atropine sulfate；Atropine sulfate monohydrate；atropine sulphate；(RS)-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenyl propanoate sulfate；1αH,5αH-tropan-3-α-ol (±)-tropate sulfate；artropine sulphate；atropin sulfate；hyoscyamine sulfate
• CAS: 5908-99-6；55-48-1；300-40-3；620-61-1；1867-24-9；2472-17-5；2623-69-0；14844-27-0
• 化学式: C₁₇H₂₃NO₃*H₂O₄S
• 分子量: 387.454
• InChiKey: VJFQPODMEGSXHC-RIMUKSHESA-N

物化性质

• 稳定性/保质期：

  常温常压下，这种物质稳定存在，表现为无色结晶体或白色结晶粉末。其熔点为190-194℃。每克晶体可溶解于以下溶剂：0.4毫升水、2.5毫升沸醇、5毫升醇、2.5毫升甘油、420毫升氯仿以及3000毫升乙醚。该物质无臭，具有风化性，遇光易变质，并且味道极为苦涩，剧毒。

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  26.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  124.37
• 氢给体数：
  3.0
• 氢受体数：
  6.0

安全信息

• 危险品标志：
  T+
• 安全说明：
  S1,S23,S26,S36/37/39,S45
• 危险类别码：
  R36/37/38,R43,R26/28
• WGK Germany：
  2
• 海关编码：
  29399900
• 危险品运输编号：
  UN 1544 6.1/PG 2
• 危险类别：
  6.1
• RTECS号：
  CK2455000
• 包装等级：
  II

SDS

Name:	Atropine Sulfate Monohydrate 98.5% (Dry Substance) Material Safety Data Sheet
Synonym:	None known
CAS:	5908-99-6

Section 1 - Chemical Product MSDS Name:Atropine Sulfate Monohydrate 98.5% (Dry Substance) Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5908-99-6	Atropine Sulfate Monohydrate	98.5	unlisted

Hazard Symbols: T+
Risk Phrases: 26/28

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Very toxic by inhalation and if swallowed.Light sensitive.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. May cause lacrimation (tearing), blurred vision, and photophobia.
Skin:
May cause skin irritation. May cause skin rash and eruptions.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Ingestion of large amounts may cause pain, constipation or diarrhea.
May cause an abrupt rise in body temperature, convulsions, and coma.
Ingestion may cause headache, nausea, and vomiting.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May cause cardiovascular disturbances, hearing abnormalities, central nervous system depression, muscle weakness, and possible death due to respiratory failure.
Chronic:
Exposure to large doses may cause central nervous system depression.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Store protected from light.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from light.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5908-99-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 189.00 - 192.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble
Specific Gravity/Density:
Molecular Formula: C34H46N2O6.H2SO4.H2O
Molecular Weight: 694.85

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5908-99-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Atropine Sulfate Monohydrate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: ALKALOID SALTS, SOLID, N.O.S.*
Hazard Class: 6.1
UN Number: 1544
Packing Group: II
IMO
Shipping Name: ALKALOID SALTS, SOLID, N.O.S.
Hazard Class: 6.1
UN Number: 1544
Packing Group: II
RID/ADR
Shipping Name: ALKALOID SALTS, SOLID, N.O.S.
Hazard Class: 6.1
UN Number: 1544
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T+
Risk Phrases:
R 26/28 Very toxic by inhalation and if swallowed.
Safety Phrases:
S 1 Keep locked up.
S 25 Avoid contact with eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 5908-99-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5908-99-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5908-99-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

类别：有毒物品
毒性分级：高毒
急性毒性：静脉-小鼠 LD50: 78 毫克/公斤
可燃性危险特性：可燃；燃烧时产生有毒的氮氧化物和硫氧化物烟雾
储运特性：通风、低温干燥；与库房食品原料分开存放
灭火剂：干粉、泡沫、沙土、二氧化碳、雾状水

反应信息

• 作为反应物：
  描述：

  8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate sulfate (1:1) 在 sodium hydroxide 作用下， 以 水 为溶剂， 以90%的产率得到Atropine
  参考文献：
  名称：

  아트로핀의 제조방법

  摘要：

  本发明涉及阿托品的生产方法。更具体地说，本发明是一种通过使用活性炭有效地去除在阿托品硫酸盐水合物中残留的杂质，并通过酸-碱反应使硫酸盐脱离，从而制造和结晶化阿托品，以获得高纯度阿托品的阿托品生产方法。

  公开号：

  KR20190102899A
• 作为产物：
  描述：

  Atropine 在 硫酸 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 3.5h， 以85 g的产率得到8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate sulfate (1:1)
  参考文献：
  名称：

  [EN] CRYSTALLINE ATROPINE SULFATE
  [FR] SULFATE D'ATROPINE CRISTALLINE

  摘要：

  本发明涉及硫酸阿托品的晶型多态形式及其制备方法。

  公开号：

  WO2014102829A1

文献信息

• [EN] 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS<br/>[FR] COMPOSÉS 3,5-DIAMINO -6-CHLORO-N-(N- (4-PHÉNYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2-CARBOXAMIDE
  申请人：PARION SCIENCES INC

  公开号：WO2014099673A1

  公开（公告）日：2014-06-26

  The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.

  本发明涉及以下化合物的公式：或其药学上可接受的盐，用作钠通道阻滞剂，以及含有这些化合物的组合物，制备这些化合物的方法，以及在促进粘膜表面水合和治疗包括囊性纤维化、慢性阻塞性肺病、哮喘、支气管扩张、急性和慢性支气管炎、肺气肿和肺炎等疾病的治疗方法。
• CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY
  申请人：Parion Sciences, Inc.

  公开号：US20140171447A1

  公开（公告）日：2014-06-19

  This invention provides compounds of the formula I: and their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.

  这项发明提供了式I的化合物及其药用盐，可用作钠通道阻滞剂，包含这些化合物的组合物，以及用于这些化合物的治疗方法和用途，以及制备这些化合物的方法。
• NICOTINIC RECEPTOR NON-COMPETITIVE MODULATORS
  申请人：Targacept, Inc.

  公开号：US20140288185A1

  公开（公告）日：2014-09-25

  The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

  本发明涉及调节尼古丁受体作为非竞争性拮抗剂的化合物，其合成方法，使用方法以及它们的药物组成。
• USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS
  申请人：PAPKE Roger L.

  公开号：US20100179186A1

  公开（公告）日：2010-07-15

  This application provides a method for the use of select quaternary ammonium antagonists to alpha-7 nAChR for the treatment of cancer and HIV and AIDS.

  该应用程序提供了一种使用选择性四价铵拮抗剂对α-7 nAChR进行治疗癌症、HIV和艾滋病的方法。
• Azabicycloalkane compounds
  申请人：——

  公开号：US20040242622A1

  公开（公告）日：2004-12-02

  This invention provides compounds of formula I: 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both &bgr; 2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Such compounds are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

  这项发明提供了式I的化合物： 其中R1、R2、R3、R4、R5、R6和R7如规范中所定义，或其药用可接受盐、溶剂或立体异构体。本发明的化合物具有β2肾上腺素受体激动剂和肌碱受体拮抗剂活性。这些化合物对治疗肺部疾病，如慢性阻塞性肺病和哮喘，是有用的。